Logo image of CRML

CRITICAL METALS CORP (CRML) Stock Fundamental Analysis

NASDAQ:CRML - Nasdaq - VGG2662B1031 - Common Stock - Currency: USD

2.49  +0.24 (+10.67%)

After market: 2.38 -0.11 (-4.42%)

Fundamental Rating

1

CRML gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 152 industry peers in the Metals & Mining industry. CRML has a bad profitability rating. Also its financial health evaluation is rather negative. CRML does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CRML had negative earnings in the past year.
In the past year CRML has reported a negative cash flow from operations.
CRML Yearly Net Income VS EBIT VS OCF VS FCFCRML Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -500K -1M -1.5M -2M

1.2 Ratios

CRML has a worse Return On Assets (-20.02%) than 78.29% of its industry peers.
Looking at the Return On Equity, with a value of -22.62%, CRML is doing worse than 74.34% of the companies in the same industry.
Industry RankSector Rank
ROA -20.02%
ROE -22.62%
ROIC N/A
ROA(3y)-0.18%
ROA(5y)N/A
ROE(3y)-0.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRML Yearly ROA, ROE, ROICCRML Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 -0.2 -0.4 -0.6 -0.8 -1

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRML so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRML Yearly Profit, Operating, Gross MarginsCRML Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, CRML has about the same amount of shares outstanding.
Compared to 1 year ago, CRML has an improved debt to assets ratio.
CRML Yearly Shares OutstandingCRML Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 5M 10M 15M 20M
CRML Yearly Total Debt VS Total AssetsCRML Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

CRML has an Altman-Z score of 35.35. This indicates that CRML is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 35.35, CRML belongs to the best of the industry, outperforming 89.47% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that CRML is not too dependend on debt financing.
The Debt to Equity ratio of CRML (0.00) is better than 84.87% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 35.35
ROIC/WACCN/A
WACCN/A
CRML Yearly LT Debt VS Equity VS FCFCRML Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 0.08 indicates that CRML may have some problems paying its short term obligations.
CRML's Current ratio of 0.08 is on the low side compared to the rest of the industry. CRML is outperformed by 94.74% of its industry peers.
CRML has a Quick Ratio of 0.08. This is a bad value and indicates that CRML is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.08, CRML is doing worse than 94.74% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.08
Quick Ratio 0.08
CRML Yearly Current Assets VS Current LiabilitesCRML Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 500K 1M 1.5M

More info and screens

0

3. Growth

3.1 Past

CRML shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.60%.
EPS 1Y (TTM)-16.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CRML reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRML Price Earnings VS Forward Price EarningsCRML Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRML Per share dataCRML EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CRML does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRITICAL METALS CORP

NASDAQ:CRML (4/17/2025, 8:10:55 PM)

After market: 2.38 -0.11 (-4.42%)

2.49

+0.24 (+10.67%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners10.59%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap238.09M
AnalystsN/A
Price TargetN/A
Short Float %2.99%
Short Ratio1.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.44
P/tB 7.44
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0
BVpS0.33
TBVpS0.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.02%
ROE -22.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-0.18%
ROA(5y)N/A
ROE(3y)-0.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.08
Quick Ratio 0.08
Altman-Z 35.35
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.75%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y38.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-563.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-188.18%
OCF growth 3YN/A
OCF growth 5YN/A